### Index

#### A
- Affinity, 163, 167
- Agonism, 201
- Akaike Information Criterion, 287
- Alternative parameterization, 177, 192
- Alzheimer’s disease, 305, 307, 320, 321
- Antibody engineering, 435
- Anti-diabetic drugs, 473
- Area-under-the-curve (AUC), 481, 486
- Ariens equation, 171
- Asynchronous, 83, 87–91
- Automated, 288, 289, 297
- Autoregulation, 229, 231, 242, 243, 246

#### B
- Bacterial growth model, 382
- Baroreflex components, 140
- Between-subject variability, 257, 258, 261, 264, 266, 269
- Bioinformatics, 15, 20, 54, 56, 70, 330
- Biological homeostasis, 93
- Biomarkers, 278, 421, 422, 424, 425, 428, 432, 438, 439, 441, 447
- Biophase model, 184, 186
- Biosensor process, 178
- Biosignal flux, 178
- Bone remodeling, 43
- Boolean functions, 86, 87

#### C
- Calibration, 307, 309, 311, 315, 319, 320
- Capacity, 162, 165, 167, 170, 172
- Cardiotoxicity, 21, 22
- Cardiovascular control, 140
- Central sleep apnea (CSA), 138, 153, 154
- Chemical equilibrium, 212, 214
- Cheminformatics, 15, 20, 22
- Clinical trials, 325, 343
- Closed-loop system, 139–142, 144, 146, 147, 149, 155, 156
- Combination regimen, 376, 422, 424, 428, 445, 451
- Concentration, 178, 180, 183, 186, 187, 193, 200, 203
- Concentration-effect relationship, 214
- Controller, 231–233
- Covariates, 261, 273
- Cross-system interactions, 328
- Crosstalk, 106
- Cytochrome P450, 56, 59
- Cytotoxic chemotherapies, 421

#### D
- Dalla Man model, 482
- Deterministic, 87, 88, 90
- Direct-acting antiviral (DAA), 404, 414, 416
- Direct effect, 177–179, 183, 186
- Direct-effect model, 223, 224
- Disease progression, 341
- Dose selection, 421, 451, 452
- Drug-biological interface, 161
- Drug-drug interactions (DDI), 17, 19
- Druggability, 61, 64, 66
- Drug potency, 269
- Drug target selection, 421

#### E
- Enhanced pharmacodynamic (ePD) models, 107
- Epidermal derived growth factor receptor (Egfr), 81
- Epistasis, 308
- Erlotinib, 354, 355, 357, 359, 362, 364, 365
- Euglycemic clamp, 475

#### F
- Feedback, 106, 113, 120
Feedback Control Indirect Response (FC IDR), 229, 231, 239, 250
Feedback regulation, 229–231, 234, 239, 242, 243, 245, 248, 249, 252
Feedforward, 106
Fick’s Laws, 163
Frayn’s text, 471

G
Gaddum equation, 171
GenBank, 57
Gene-drug interactions (GDI), 17, 19
Gene-gene interaction, 306, 308
Genomic variation, 59, 63, 65
Gluconeogenesis, 471
Glutamatergic systems, 307
Grodin, 230

H
Hepatotoxicity, 22
High-dimensional data sets, 277
Homeostasis, 138, 168–170, 326, 331–333, 339
Horizontal integration, 451
Hormone synthesis, 480
Hyperglycemic clamp, 475
Hyperinsulinemic, 475, 476
Hypothermia, 264

I
Immunomodulatory signals, 326, 333, 335, 338
Indirect response, 177, 187, 188, 191, 196, 198
Individualized therapy, 298
Informative genes, 285
Inputs, 310, 311
Input signal, 106
In silico, 343
In silico model, 305
Insulin analogs, 473
Interactome, 60
Interferon, 403, 404, 412, 416
Interferon-free regimens, 414, 417
Intravenous Glucose Tolerance Test (IVGTT), 475
In vitro models, 328, 376–378
In vitro studies, 35
In vivo, 374, 376, 377, 379–381, 385
In vivo studies, 34, 36
Irreversible drug action, 220

L
Limit of detection (LOD), 404, 405, 412, 416–418
Linear feedback, 231, 232, 234, 239

M
MAO-A inhibitors, 307
MAPK signaling, 97
MAPK/ERK signaling pathway, 231
Mean arterial pressure (MAP), 139–148
Mechanical effect of respiration (MER), 146
Mechanism-based computational models, 421
Mechanism of action, 218, 219, 224, 225
Metabolic control, 151, 156
Metabolic fluxes, 467, 480
Michaelis-Menten equations, 116
Microcircuit parameters, 313
Microdomains, 116
Minimal modeling, 145, 148, 150
Minimum Inhibitory Concentration (MIC), 373, 374, 385, 391
Model-based liposome design, 436
Model qualification, 489
Model qualification method, 46
Monoexponential, 258
Multidimensional, 296, 297
Multimodal distributions, 269
Multi-scale modeling, 7
Multi-state discrete models, 94
Multi-variant model, 406, 408
Myeloperoxidase (MPO), 270

N
Nerve Growth Factor (NGF), 35
Network-based, 55, 62
Network-based model, 372, 396
Network redundancy, 427
Nodes, 53, 65, 69
Nonlinear mixed-effect (NLME), 417
Nonlinear mixed effects models (NMEMs), 255, 256

O
Occam’s Razor, 110, 116
Olanzapine metabolism, 309
Oncogene, 354, 357
Oncogenic signaling networks, 425
Ontology, 21
Open-loop system, 139, 141, 142, 149
Open system models, 377
Operational efficacy, 167
Optimal sequencing, 376
Oral Glucose Tolerance Test (OGTT), 469, 475, 486
Ordinary Differential Equation (ODE), 118
Orthogonal computational modeling approaches, 421
Outputs, 309–311, 313, 320
Overparameterization, 261

P
Parameterization, 411
Parameter values, 117, 121, 126–129
 Parsimony, 286, 287, 289
Patient stratification, 421
Personalized medicine, 56, 64, 70
Perturbations, 83, 93, 95, 106, 122, 123, 125
Pharmacogenetics, 308
Pharmacogenomics, 56, 59
Pharmacokinetics/Pharmacodynamics, 4
Physicochemical-based models, 430, 435
Physiological based pharmacokinetic (PBPK) models, 15
Plasma concentration, 234, 246, 248
PNEUMA, 151–155
Polymorphonuclear lymphocytes (PMNs), 392, 395
Polypharmacy, 305–308
Power model, 179, 182
Pre-competitive data, 23
Protein linkage network, 359, 364
Protein–protein interactions (PPI), 53, 60, 61, 64

Q
Quantitative Systems Pharmacology (QSP), 27, 30
Quasi-mechanistic, 329

R
Rasgap state, 97
Reaction rate laws, 116, 119
Receptor occupancy theory, 177, 181
Regression, 281, 282, 289, 292, 296
Rheumatoid Arthritis, 32, 41

S
Schwarz Information Criterion, 287
Sequencing methods, 414
Signal transduction, 177, 200, 201
Skin inflammation, 357, 359, 364, 365
Sleep-wake state, 155, 156
Slow dissociation, 215, 219, 224
State transition, 87, 88, 90, 91
Statistical, 326, 331, 334
Statistical models, 421, 429, 441, 448
Stochasticity, 336
Stoichiometries, 118, 119
Structured modeling, 150, 156
Substrate control, 165
Sustained virologic response (SVR), 404, 405, 408, 410, 412–417
Synchronous, 83, 87, 90, 91
Systems biology, 4, 7
Systems model, 7, 10, 11, 12
Systems pharmacology, 4, 5, 7, 10, 11
Systems physiology, 5

T
Target, 211, 212, 215, 217, 220, 222, 225
Target-binding, 169
Target values, 375
Telaprevir, 405, 406, 408–410, 412, 414
Therapeutic areas, 37
Therapeutic design, 421, 437, 451
Time-kill culture tubes, 377
Total peripheral resistance (TPR), 139–149, 152
Transit compartment model, 201, 202, 205
Trial design, 310, 311, 321
Tricyclic, 307
Turnover, 168–172
Turnover model, 217, 222
Turnover rates, 270, 273

V
Variability, 255–258, 262, 264, 269, 273
Vertical integration, 451

W
Windkessel model, 145, 146